Tuberculosis continues to be a major public health threat around the world. The estimate that more lives may have been lost in 2009 due to tuberculosis than in any year in history is alarming 4 . An increasing number of cases reporting infection with multidrug-resistant and extensively drug-resistant (XDR) strains of M. tuberculosis have diminished the capability to respond effectively against this threat. A recent study reporting high mortality rates of individuals concurrently infected with HIV and XDR tuberculosis illustrates the need for new drugs to treat tuberculosis 5 . A major reason for the emergence of drug resistance is thought to be poor compliance to treatment regimens, as the current therapy requires a combination of drugs to be taken daily for 6 months or more 4 . Although >99% of M. tuberculosis bacilli are killed within 2 weeks, it takes the remainder of the therapy to effectively kill the surviving population 6 . These bacilli, broadly defined as 'persisters' , are able to transiently tolerate drugs. The phenomenon of persistence is poorly understood. In vitro models designed to mimic the physiology of persisters are based on exposure to nitric oxide and depletion of oxygen and nutrients, as these conditions are thought to prevail in a persisting infection in vivo [7] [8] [9] .
A higher percentage of Escherichia coli bacilli are able to survive exposure to drugs and persist at stationary phase as compared to bacteria in the exponential phase of growth 10 . Little is known about changes in the cell wall during the chronic phase of infection and whether it regulates persistence of M. tuberculosis in the host. Understanding the regulation of cell wall physiology and its consequences may enable us to effectively target and kill persisters by interfering with this process. The cell wall of M. tuberculosis accounts for up to 40% of the cell's dry mass, as compared to 5% and 10% in Gram-positive and Gram-negative bacteria, respectively 11 . It is thought that the degree of peptidoglycan cross-linking is ~50% in E. coli 12 , whereas it is ~70%-80% in Mycobacterium species 13 . Mycobacterial peptidoglycan layer is cross-linked with both 4→3 and 3→3 linkages 1 . Recently, it was shown that 80% of the transpeptide linkages in the peptidoglycan of M. tuberculosis at stationary phase are of the nonclassical 3→3 type 2 . Here we report identification of a gene, MT2594 (hereafter reannotated as ldt Mt2 ), that encodes an l,d-transpeptidase for synthesis of nonclassical 3→3 cross-linkages and show that inactivation of the gene results in altered colony morphology, attenuation of persistence and increased susceptibility to amoxicillin/clavulanate both in vitro and in the mouse model of tuberculosis.
We isolated a mutant M. tuberculosis resulting from inactivation of ldt Mt2 , by screening a collection of 5,100 unique transposon insertion mutants for growth attenuation 14 . Colonies of this mutant (ldt Mt2 Tn) were small, smooth and had punctuated aerial growth rather than the typical large, rough and laterally diffuse morphology observed in the parent strain (Fig. 1a) , despite the lack of difference in the composition of the lipids that constitute the cell wall (Supplementary Fig. 1 ). Liquid broth cultures of the mutant strain reached lower optical and cell densities compared with the parental strain (Fig. 1b) . The wild-type
The Mycobacterium tuberculosis protein Ldt Mt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin phenotype was restored upon complementation of the mutant with a single copy of the gene (Fig. 1a,b) . The ratio of colony-forming units (CFUs) of the mutant to WT at the beginning of the growth assay was 10:1, whereas after 192 h it was 1:100. These data show that there was a ~1,000-fold larger increase in the wild-type population over 192 h compared to the mutant strain. We derived doubling times of 18.1 h, 14.5 h and 14.8 h from CFU data for the mutant, wild-type and complemented strains, respectively. Ldt Mt2 is annotated as a hypothetical protein with an unknown function. The amino terminus contains a putative single transmembrane domain (positions 20-42), anchoring the remainder of the protein.
The carboxy-terminal region of MT2594 is similar to the catalytic domain of the prototypic peptidoglycan l,d-transpeptidase from Enterococcus faecium (29% identity), including the active site cysteine residue within the invariant SHGC motif 15 (Fig. 2a) . To determine whether ldt Mt2 encodes a functional l,d-transpeptidase, we produced a soluble fragment of the protein in E. coli that we purified and assayed for cross-linking activity (Fig. 2b) . The substrate was a disaccharide-tetrapeptide monomer isolated from the peptidoglycan of Corynebacterium jeikeium, which has the same structure as the predominant monomer of M. tuberculosis 16 (Fig. 2c) . Ldt Mt2 did not catalyze the formation of dimers with disaccharide-peptide containing a stem pentapeptide. Thus, Ldt Mt2 is specific for stem tetrapeptides, as are Ldt Mt1 (ref.
2) and the prototypic l,d-transpeptidase from E. faecium 15 . These results show that MT2594 is an l,d-transpeptidase that catalyzes the formation of 3→3 peptidoglycan cross-links.
Further investigation revealed four putative paralogs of ldt Mt2 in the genome of M. tuberculosis (MT0125, MT0202, MT0501 and MT1477).
To gain an insight into the level of expression of the five paralogs, we performed quantitative RT-PCR analyses on eight RNA samples prepared from the exponential and stationary phases of growth. The ldt Mt2 messenger RNA was at least fivefold more abundant than the combined expression of the four paralogs ( Supplementary Fig. 2 ). Next, we assessed their functional relevance to l,d-transpeptidation. Mutants lacking MT0202, MT0501 and MT1477 have morphologies and growth phenotypes similar to those of the parent wildtype strain (Supplementary Fig. 3 ). We purified MT0202, MT0501 and MT1477 but did not detect any l,d-transpeptidase activity with the peptidoglycan precursor as the substrate (data not shown). MT0125 of M. tuberculosis strain CDC1551 is identical to Rv0116c of strain H 37 Rv, a gene designated ldt Mt1 that was recently shown to also encode a peptidoglycan l,d-transpeptidase 2 . Of the two l,d-transpeptidase-encoding genes, ldt Mt2 was expressed at a level at least tenfold higher than ldt Mt1 at all phases of growth (Fig. 2d) . The morphology, growth and virulence-deficient phenotype of the ldt Mt2 mutant indicates that low-level expression of ldt Mt1 does not compensate for the loss of the l,d-transpeptidase activity of MT2594, although analysis of the peptidoglycan structure showed that 3→3 cross-linkages were synthesized by Ldt Mt1 in stationary phase culture of the mutant (Supplementary Fig. 4) . Next, we assessed whether inactivation of ldt Mt2 affects the in vivo growth and virulence of M. tuberculosis. We implanted approximately 3 × 10 3 CFUs of each strain in the lungs of three groups of immunocompetent BALB/c mice. The ldt Mt2 mutant established infection and showed a normal growth pattern during the first 2 weeks but stopped proliferating beyond this stage of infection ( Fig. 3a and Supplementary Fig. 5 ). The wild-type and the complemented strains proliferated rapidly until 4 weeks after infection, at which stage a heavy bacterial burden caused the mice to die (Fig. 3a) . The median survival times for the wild-type-infected and complemented strain-infected groups were 38 d and 30 d, respectively (Fig. 3b) . The mice infected with the mutant strain did not die, and we did not observe any signs of morbidity despite the presence of ~1 × 10 4 CFUs in the lungs during the persistent stage of infection (Fig. 3b) .
The nonclassical 3→3 linkages comprises the majority of the transpeptide linkages in nonreplicating M. tuberculosis 2 . We hypothesized that the loss of Ldt Mt2 may compromise the mutant's ability to adapt during the chronic phase of infection, a crucial stage in the pathogenesis of tuberculosis. If the failure in adaptation was the result of a defect in peptidoglycan cross-linking by Ldt Mt2 , another consequence could be an increased susceptibility to β-lactams. We tested this hypothesis by assessing the susceptibility of the Ldt Mt2 mutant to amoxicillin. M. tuberculosis produces a β-lactamase that is inactivated by clavulanic acid 17 . The minimum inhibitory concentration (MIC) of the commercially available clavulanic acid-amoxicillin combination (Augmentin) was 1.2 µg ml −1 and 0.14 µg ml −1 for the wild-type and mutant strains, respectively. Loss of MT2594 did not alter susceptibility to isoniazid (MIC = 0.03 µg ml −1 ) and d-cycloserine (5 µg ml −1 ). Thus, loss of Ldt Mt2 was associated with increased susceptibility to amoxicillin in the presence of the clavulanic acid that inhibited the β-lactamase. A recent study assessed the susceptibility of the drug-sensitive laboratory strain H 37 Rv and 13 XDR strains of M. tuberculosis to amoxicillin 3 . Whereas H 37 Rv was found to be resistant to amoxicillin-clavulanate, all 13 XDR strains were highly susceptible, with an MIC ranging from 0.32 µg ml −1 to 10 µg ml −1 . It has been reported that amoxicillin-clavulanate lacks early bactericidal activity, a measure of effectiveness of the drugs during the first 2 d of treatment 18 . However, amoxicillin-clavulanate has also been used to treat patients with multidrug-resistant tuberculosis 19 . An explanation for these observations is that amoxicillin-clavulanate lacks potency during the early phase but shows activity during the extended phase of treatment.
Next we assessed the susceptibility of the mutant strain to amoxicillin in mice. We treated mice infected with either the wild-type M. tuberculosis or the mutant strain with PBS as a placebo, 25 mg per kg body weight isoniazid or 200 mg per kg body weight amoxicillin in plus 50 mg per kg body weight clavulanate (Fig. 3c-f) . Isoniazid was similarly effective against both the wild-type and the mutant strains (Fig. 3e) . The bacterial burden in mice infected with the wild-type strain treated with amoxicillin-clavulanate was similar to that in the group that received no treatment placebo (Fig. 3d,f) . Amoxicillin-clavulanate was ineffective during the first 2 weeks of treatment in mice infected with the mutant strain, as the bacterial burden remained unchanged (Fig. 3f) . However, we observed a decrease in CFU of more than 2 log 10 between 2 and 4 weeks of treatment, illustrating that the mutant is susceptible to amoxicillin-clavulanate only during the chronic phase of infection (Fig. 3f) . All bacteria possess an elaborate peptidoglycan layer in their cell wall. In E. coli, the main interpeptide cross-linking occurs between the penultimate d-alanine at the fourth position of the donor and mesodiaminopimelate at the third position of the acceptor. Formation of this 4→3 bond is catalyzed by d,d-transpeptidases, which are the essential targets of β-lactam antibiotics 20 . The drugs are structural analogs of the d-Ala-d-Ala extremity of the peptidoglycan precursors and act as suicide substrates in an acylation reaction 21 . E. coli has served as the model organism for studying peptidoglycan metabolism, but the existing paradigm built upon this organism is incomplete. In this classical model, the peptidoglycan layer is regarded as a static network involving polymerization of glycan chains and cross-linking of adjacent chains by formation of 4→3 peptide bonds (Fig. 4a) 22 . On the basis of our current data and our recent findings 2 , we propose a model representing the peptidoglycan layer as a dynamic structure whose interpeptide linkages are altered as an adaptive response to a change in the environment and growth phase (Fig. 4b) . The peptide chains of the peptidoglycan layer are linked with both 4→3 and 3→3 bonds.
In addition to transpeptidases, endo-and carboxypeptidases are also present in bacteria and function to modify the peptidoglycan network 23 . These enzymes have yet to be definitively identified in M. tuberculosis. A recent report showed that the gene pgdA encodes an N-deacetylase that is involved in modification of the peptidoglycan layer in Listeria monocytogenes 24 . A putative homolog of pgdA exists in M. tuberculosis. This gene, MT1128 (Rv1096), has yet to be characterized, and its in vivo function has not been identified. Although MT2594 is a 3→3 transpeptidase, its loss and the accompanying changes in cross-linking may have pleiotropic effects on the metabolism of the peptidoglycan layer.
In this report, we have shown a new molecular basis of 3→3 linkages and their physiological role for viability and virulence of M. tuberculosis. We have also shown that l,d-transpeptidation is required for resistance to killing by amoxicillin-clavulanate and that inhibition of Ldt Mt2 alone may be sufficient to target the 3→3 linkages, despite the presence of Ldt Mt1 . It may be inferred from our findings that both 3→3 and 4→3 transpeptide linkages need to be destroyed to effectively kill M. tuberculosis. We have presented an unexploited enzyme in the pathway that can be targeted by one of the most successful groups of antibiotics in human clinical use, β-lactams. Therefore, a regimen containing a combination of inhibitors of l,d-transpeptidase and β-lactamase and a β-lactam may be able to kill M. tuberculosis by comprehensively destroying the peptidoglycan layer. As the peptidoglycan layer is a vital structure of the bacterial cell wall, insight and applications resulting from studies in M. tuberculosis will probably be broadly applicable to other bacteria.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
